Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells

J. M.C. McGee, M. R. Patten, K. F. Malnar, J. A. Price, J. S. Mayes, G. H. Watson

Research output: Contribution to journalArticle

Abstract

Immunotherapy for melanoma shows promise. Our previous whole tumor (WT) vaccine was noted to have positive clinical effects. We have now developed a new, safer melanoma vaccine that is derived from IIB-MEL-J tissue culture (TC) cells. In this study, we compare by Western blot analyses the antigens in the WT vaccine to antigens in the TC vaccine. Sera from 12 WT vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 controls served as a source of antibodies to investigate potential antigens in the vaccines. Three major antigenic peptides with approximate molecular weighs of 46, 40, and 36 kDA were present in both vaccines, while two other antigenic peptides with approximate molecular weighs of 68 and 48 kDA were present only in the TC vaccine. The reaction was similar between the patients who received the WT vaccine and those who did not receive the vaccine. Some of the individuals who did not have melanoma showed some reaction, but not to the extent of the melanoma patients. The intensity of immunostaining was greater for the TC vaccine when compared to the WT vaccine, indicating that these proteins are in a higher concentration in the TC vaccine. This new vaccine from IIB-MEL-J tissue culture cells provides a higher yield and a much more consistent source of potentially clinically relevant antigens without risk of infection or contamination by other irrelevant materials.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number3
DOIs
StatePublished - 1 Jan 1999

Fingerprint

Melanoma-Specific Antigens
Cancer Vaccines
Vaccines
Melanoma
Antigens
Immunotherapy
Cell Culture Techniques
Peptides
Western Blotting

Keywords

  • Antibodies
  • Melanoma antigens
  • Melanoma tissue culture cells
  • Melanoma vaccines
  • Western blot

Cite this

McGee, J. M.C. ; Patten, M. R. ; Malnar, K. F. ; Price, J. A. ; Mayes, J. S. ; Watson, G. H. / Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells. In: Cancer Biotherapy and Radiopharmaceuticals. 1999 ; Vol. 14, No. 3. pp. 203-208.
@article{2457e8c896b643a98181ac58cf37fada,
title = "Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells",
abstract = "Immunotherapy for melanoma shows promise. Our previous whole tumor (WT) vaccine was noted to have positive clinical effects. We have now developed a new, safer melanoma vaccine that is derived from IIB-MEL-J tissue culture (TC) cells. In this study, we compare by Western blot analyses the antigens in the WT vaccine to antigens in the TC vaccine. Sera from 12 WT vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 controls served as a source of antibodies to investigate potential antigens in the vaccines. Three major antigenic peptides with approximate molecular weighs of 46, 40, and 36 kDA were present in both vaccines, while two other antigenic peptides with approximate molecular weighs of 68 and 48 kDA were present only in the TC vaccine. The reaction was similar between the patients who received the WT vaccine and those who did not receive the vaccine. Some of the individuals who did not have melanoma showed some reaction, but not to the extent of the melanoma patients. The intensity of immunostaining was greater for the TC vaccine when compared to the WT vaccine, indicating that these proteins are in a higher concentration in the TC vaccine. This new vaccine from IIB-MEL-J tissue culture cells provides a higher yield and a much more consistent source of potentially clinically relevant antigens without risk of infection or contamination by other irrelevant materials.",
keywords = "Antibodies, Melanoma antigens, Melanoma tissue culture cells, Melanoma vaccines, Western blot",
author = "McGee, {J. M.C.} and Patten, {M. R.} and Malnar, {K. F.} and Price, {J. A.} and Mayes, {J. S.} and Watson, {G. H.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1089/cbr.1999.14.203",
language = "English",
volume = "14",
pages = "203--208",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells. / McGee, J. M.C.; Patten, M. R.; Malnar, K. F.; Price, J. A.; Mayes, J. S.; Watson, G. H.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 14, No. 3, 01.01.1999, p. 203-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells

AU - McGee, J. M.C.

AU - Patten, M. R.

AU - Malnar, K. F.

AU - Price, J. A.

AU - Mayes, J. S.

AU - Watson, G. H.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Immunotherapy for melanoma shows promise. Our previous whole tumor (WT) vaccine was noted to have positive clinical effects. We have now developed a new, safer melanoma vaccine that is derived from IIB-MEL-J tissue culture (TC) cells. In this study, we compare by Western blot analyses the antigens in the WT vaccine to antigens in the TC vaccine. Sera from 12 WT vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 controls served as a source of antibodies to investigate potential antigens in the vaccines. Three major antigenic peptides with approximate molecular weighs of 46, 40, and 36 kDA were present in both vaccines, while two other antigenic peptides with approximate molecular weighs of 68 and 48 kDA were present only in the TC vaccine. The reaction was similar between the patients who received the WT vaccine and those who did not receive the vaccine. Some of the individuals who did not have melanoma showed some reaction, but not to the extent of the melanoma patients. The intensity of immunostaining was greater for the TC vaccine when compared to the WT vaccine, indicating that these proteins are in a higher concentration in the TC vaccine. This new vaccine from IIB-MEL-J tissue culture cells provides a higher yield and a much more consistent source of potentially clinically relevant antigens without risk of infection or contamination by other irrelevant materials.

AB - Immunotherapy for melanoma shows promise. Our previous whole tumor (WT) vaccine was noted to have positive clinical effects. We have now developed a new, safer melanoma vaccine that is derived from IIB-MEL-J tissue culture (TC) cells. In this study, we compare by Western blot analyses the antigens in the WT vaccine to antigens in the TC vaccine. Sera from 12 WT vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 controls served as a source of antibodies to investigate potential antigens in the vaccines. Three major antigenic peptides with approximate molecular weighs of 46, 40, and 36 kDA were present in both vaccines, while two other antigenic peptides with approximate molecular weighs of 68 and 48 kDA were present only in the TC vaccine. The reaction was similar between the patients who received the WT vaccine and those who did not receive the vaccine. Some of the individuals who did not have melanoma showed some reaction, but not to the extent of the melanoma patients. The intensity of immunostaining was greater for the TC vaccine when compared to the WT vaccine, indicating that these proteins are in a higher concentration in the TC vaccine. This new vaccine from IIB-MEL-J tissue culture cells provides a higher yield and a much more consistent source of potentially clinically relevant antigens without risk of infection or contamination by other irrelevant materials.

KW - Antibodies

KW - Melanoma antigens

KW - Melanoma tissue culture cells

KW - Melanoma vaccines

KW - Western blot

UR - http://www.scopus.com/inward/record.url?scp=0033066282&partnerID=8YFLogxK

U2 - 10.1089/cbr.1999.14.203

DO - 10.1089/cbr.1999.14.203

M3 - Article

C2 - 10850304

AN - SCOPUS:0033066282

VL - 14

SP - 203

EP - 208

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -